Pharmafile Logo

AbbVie Inc

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for AbbVie Inc in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring AbbVie Inc.

Recent articles on PMLiVE featuring AbbVie Inc

- PMLiVE
Helus Pharma appoints Ken Kramer as Senior VP, Medical Affairs

Kramer most recently served as VP and Head of Medical Neuroscience at Bristol Myers Squibb

- PMLiVE
Allergan Aesthetics launches Skin Quality Index for aesthetic consultations

Spanning four dimensions of skin health, the framework introduces 15 terms and definitions

- PMLiVE
N4 Pharma appoints David Solomon as CEO

The company is to be renamed Thalia Therapeutics to reflect its strategic transition

- PMLiVE
AbbVie reaches agreement for affordable prescription drugs with US government

The pharma company has also pledged a $100bn investment in US infrastructure over the next decade

- PMLiVE
BMS, Takeda and Astex join AI training consortium

The initiative focuses on training AI models to aid in drug discovery and development

- PMLiVE
Inizio appoints Ryan Quigley as new CEO

Ryan was previously COO at Inizio and has worked in the industry for 25 years

- PMLiVE
AbbVie/Genmab’s lymphoma drug shows promise in phase 3 combination trial

Follicular lymphoma affects around 15,000 people in the US every year

- PMLiVE
AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

Around 700,000 people in the US are living with some form of the autoimmune disease

- PMLiVE
Eli Lilly shares positive results for Jaypirca in head-to-head CLL/SLL study

Around 23,690 cases of chronic lymphocytic leukaemia are expected to be diagnosed in the US this year

- PMLiVE
J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

- PMLiVE
AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

- PMLiVE
AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition

The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links